Article info

Download PDFPDF
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial

Authors

  1. Correspondence to Professor Peter C Taylor, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford OX3 7LD, UK; peter.taylor{at}kennedy.ox.ac.uk
View Full Text

Citation

Sweet K, Dasgupta B, de Vries D, et al
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial

Publication history

  • Received February 5, 2019
  • Revised March 26, 2019
  • Accepted April 11, 2019
  • First published April 24, 2019.
Online issue publication 
September 12, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.